Drug intelligence / Profile preview

CTO0303-A

Development stage: Unknown
Lead developer: Taejoon Pharmaceutical
Modality: Small Molecules
Administration: Ophthalmic

Overview

**CTO0303-A** is an investigational ophthalmic eye-drop product developed by Taejoon Pharmaceutical for producing pupillary dilation during cycloplegic refraction in pediatric and adolescent subjects. It is being evaluated as an experimental arm within the CTO0303 development program in a multicenter, double-blind, randomized active-controlled Phase 2b/3 study in participants aged 4 to 15 years. Its precise active ingredient composition and molecular target have not been publicly disclosed. ([ctv.veeva.com](https://ctv.veeva.com/study/comparing-efficacy-and-safety-of-cto0303-in-pediatric-subjects))

Beyond the preview

Go deeper on CTO0303-A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTO0303-A.

Explore the full profile